Research ExplorerPublicationsCurrent use of vasopressors in septic shock

Current use of vasopressors in septic shock

Standard

Current use of vasopressors in septic shock. / Scheeren, Thomas W L; Bakker, Jan; De Backer, Daniel; Annane, Djillali; Asfar, Pierre; Boerma, E Christiaan; Cecconi, Maurizio; Dubin, Arnaldo; Dünser, Martin W; Duranteau, Jacques; Gordon, Anthony C; Hamzaoui, Olfa; Hernández, Glenn; Leone, Marc; Levy, Bruno; Martin, Claude; Mebazaa, Alexandre; Monnet, Xavier; Morelli, Andrea; Payen, Didier; Pearse, Rupert; Pinsky, Michael R; Radermacher, Peter; Reuter, Daniel; Saugel, Bernd; Sakr, Yasser; Singer, Mervyn; Squara, Pierre; Vieillard-Baron, Antoine; Vignon, Philippe; Vistisen, Simon T; van der Horst, Iwan C C; Vincent, Jean-Louis; Teboul, Jean-Louis.

In: ANN INTENSIVE CARE, Vol. 9, No. 1, 30.01.2019, p. 20.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Scheeren, TWL, Bakker, J, De Backer, D, Annane, D, Asfar, P, Boerma, EC, Cecconi, M, Dubin, A, Dünser, MW, Duranteau, J, Gordon, AC, Hamzaoui, O, Hernández, G, Leone, M, Levy, B, Martin, C, Mebazaa, A, Monnet, X, Morelli, A, Payen, D, Pearse, R, Pinsky, MR, Radermacher, P, Reuter, D, Saugel, B, Sakr, Y, Singer, M, Squara, P, Vieillard-Baron, A, Vignon, P, Vistisen, ST, van der Horst, ICC, Vincent, J-L & Teboul, J-L 2019, 'Current use of vasopressors in septic shock', ANN INTENSIVE CARE, vol. 9, no. 1, pp. 20. https://doi.org/10.1186/s13613-019-0498-7

APA

Scheeren, T. W. L., Bakker, J., De Backer, D., Annane, D., Asfar, P., Boerma, E. C., Cecconi, M., Dubin, A., Dünser, M. W., Duranteau, J., Gordon, A. C., Hamzaoui, O., Hernández, G., Leone, M., Levy, B., Martin, C., Mebazaa, A., Monnet, X., Morelli, A., ... Teboul, J-L. (2019). Current use of vasopressors in septic shock. ANN INTENSIVE CARE, 9(1), 20. https://doi.org/10.1186/s13613-019-0498-7

Vancouver

Scheeren TWL, Bakker J, De Backer D, Annane D, Asfar P, Boerma EC et al. Current use of vasopressors in septic shock. ANN INTENSIVE CARE. 2019 Jan 30;9(1):20. https://doi.org/10.1186/s13613-019-0498-7

Bibtex

@article{9fe21b0872be49f092b4f7721fb9ab0f,
title = "Current use of vasopressors in septic shock",
abstract = "BACKGROUND: Vasopressors are commonly applied to restore and maintain blood pressure in patients with sepsis. We aimed to evaluate the current practice and therapeutic goals regarding vasopressor use in septic shock as a basis for future studies and to provide some recommendations on their use.METHODS: From November 2016 to April 2017, an anonymous web-based survey on the use of vasoactive drugs was accessible to members of the European Society of Intensive Care Medicine (ESICM). A total of 17 questions focused on the profile of respondents, triggering factors, first choice agent, dosing, timing, targets, additional treatments, and effects of vasopressors. We investigated whether the answers complied with current guidelines. In addition, a group of 34 international ESICM experts was asked to formulate recommendations for the use of vasopressors based on 6 questions with sub-questions (total 14).RESULTS: A total of 839 physicians from 82 countries (65% main specialty/activity intensive care) responded. The main trigger for vasopressor use was an insufficient mean arterial pressure (MAP) response to initial fluid resuscitation (83%). The first-line vasopressor was norepinephrine (97%), targeting predominantly a MAP > 60-65 mmHg (70%), with higher targets in patients with chronic arterial hypertension (79%). The experts agreed on 10 recommendations, 9 of which were based on unanimous or strong (≥ 80%) agreement. They recommended not to delay vasopressor treatment until fluid resuscitation is completed but rather to start with norepinephrine early to achieve a target MAP of ≥ 65 mmHg.CONCLUSION: Reported vasopressor use in septic shock is compliant with contemporary guidelines. Future studies should focus on individualized treatment targets including earlier use of vasopressors.",
author = "Scheeren, {Thomas W L} and Jan Bakker and {De Backer}, Daniel and Djillali Annane and Pierre Asfar and Boerma, {E Christiaan} and Maurizio Cecconi and Arnaldo Dubin and D{\"u}nser, {Martin W} and Jacques Duranteau and Gordon, {Anthony C} and Olfa Hamzaoui and Glenn Hern{\'a}ndez and Marc Leone and Bruno Levy and Claude Martin and Alexandre Mebazaa and Xavier Monnet and Andrea Morelli and Didier Payen and Rupert Pearse and Pinsky, {Michael R} and Peter Radermacher and Daniel Reuter and Bernd Saugel and Yasser Sakr and Mervyn Singer and Pierre Squara and Antoine Vieillard-Baron and Philippe Vignon and Vistisen, {Simon T} and {van der Horst}, {Iwan C C} and Jean-Louis Vincent and Jean-Louis Teboul",
year = "2019",
month = jan,
day = "30",
doi = "10.1186/s13613-019-0498-7",
language = "English",
volume = "9",
pages = "20",
journal = "ANN INTENSIVE CARE",
issn = "2110-5820",
publisher = "Springer-Verlag GmbH and Co. KG",
number = "1",

}

RIS

TY - JOUR

T1 - Current use of vasopressors in septic shock

AU - Scheeren, Thomas W L

AU - Bakker, Jan

AU - De Backer, Daniel

AU - Annane, Djillali

AU - Asfar, Pierre

AU - Boerma, E Christiaan

AU - Cecconi, Maurizio

AU - Dubin, Arnaldo

AU - Dünser, Martin W

AU - Duranteau, Jacques

AU - Gordon, Anthony C

AU - Hamzaoui, Olfa

AU - Hernández, Glenn

AU - Leone, Marc

AU - Levy, Bruno

AU - Martin, Claude

AU - Mebazaa, Alexandre

AU - Monnet, Xavier

AU - Morelli, Andrea

AU - Payen, Didier

AU - Pearse, Rupert

AU - Pinsky, Michael R

AU - Radermacher, Peter

AU - Reuter, Daniel

AU - Saugel, Bernd

AU - Sakr, Yasser

AU - Singer, Mervyn

AU - Squara, Pierre

AU - Vieillard-Baron, Antoine

AU - Vignon, Philippe

AU - Vistisen, Simon T

AU - van der Horst, Iwan C C

AU - Vincent, Jean-Louis

AU - Teboul, Jean-Louis

PY - 2019/1/30

Y1 - 2019/1/30

N2 - BACKGROUND: Vasopressors are commonly applied to restore and maintain blood pressure in patients with sepsis. We aimed to evaluate the current practice and therapeutic goals regarding vasopressor use in septic shock as a basis for future studies and to provide some recommendations on their use.METHODS: From November 2016 to April 2017, an anonymous web-based survey on the use of vasoactive drugs was accessible to members of the European Society of Intensive Care Medicine (ESICM). A total of 17 questions focused on the profile of respondents, triggering factors, first choice agent, dosing, timing, targets, additional treatments, and effects of vasopressors. We investigated whether the answers complied with current guidelines. In addition, a group of 34 international ESICM experts was asked to formulate recommendations for the use of vasopressors based on 6 questions with sub-questions (total 14).RESULTS: A total of 839 physicians from 82 countries (65% main specialty/activity intensive care) responded. The main trigger for vasopressor use was an insufficient mean arterial pressure (MAP) response to initial fluid resuscitation (83%). The first-line vasopressor was norepinephrine (97%), targeting predominantly a MAP > 60-65 mmHg (70%), with higher targets in patients with chronic arterial hypertension (79%). The experts agreed on 10 recommendations, 9 of which were based on unanimous or strong (≥ 80%) agreement. They recommended not to delay vasopressor treatment until fluid resuscitation is completed but rather to start with norepinephrine early to achieve a target MAP of ≥ 65 mmHg.CONCLUSION: Reported vasopressor use in septic shock is compliant with contemporary guidelines. Future studies should focus on individualized treatment targets including earlier use of vasopressors.

AB - BACKGROUND: Vasopressors are commonly applied to restore and maintain blood pressure in patients with sepsis. We aimed to evaluate the current practice and therapeutic goals regarding vasopressor use in septic shock as a basis for future studies and to provide some recommendations on their use.METHODS: From November 2016 to April 2017, an anonymous web-based survey on the use of vasoactive drugs was accessible to members of the European Society of Intensive Care Medicine (ESICM). A total of 17 questions focused on the profile of respondents, triggering factors, first choice agent, dosing, timing, targets, additional treatments, and effects of vasopressors. We investigated whether the answers complied with current guidelines. In addition, a group of 34 international ESICM experts was asked to formulate recommendations for the use of vasopressors based on 6 questions with sub-questions (total 14).RESULTS: A total of 839 physicians from 82 countries (65% main specialty/activity intensive care) responded. The main trigger for vasopressor use was an insufficient mean arterial pressure (MAP) response to initial fluid resuscitation (83%). The first-line vasopressor was norepinephrine (97%), targeting predominantly a MAP > 60-65 mmHg (70%), with higher targets in patients with chronic arterial hypertension (79%). The experts agreed on 10 recommendations, 9 of which were based on unanimous or strong (≥ 80%) agreement. They recommended not to delay vasopressor treatment until fluid resuscitation is completed but rather to start with norepinephrine early to achieve a target MAP of ≥ 65 mmHg.CONCLUSION: Reported vasopressor use in septic shock is compliant with contemporary guidelines. Future studies should focus on individualized treatment targets including earlier use of vasopressors.

U2 - 10.1186/s13613-019-0498-7

DO - 10.1186/s13613-019-0498-7

M3 - SCORING: Journal article

C2 - 30701448

VL - 9

SP - 20

JO - ANN INTENSIVE CARE

JF - ANN INTENSIVE CARE

SN - 2110-5820

IS - 1

ER -